000			a
999			_c17319 _d17319
003			OSt
005			20220825100559.0
008			220825b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_917584 _aHaq, Afzal Asif
245			_aInterstitial cystitis-critical assessment of current treatment and opportunities for nanodelivery
250			_aVol.56(3), Jul-Sep
260			_aKarnataka _bAssociation of Pharmaceutical Teachers of India (APTI) _c2022
300			_a636-645p.
520			_aThe characteristic feature of Interstitial cystitis (IC) or bladder pain syndrome is augmented, pressure, or inconvenience in the suprapubic or bladder region. The causative factors for IC are not completely understood however certain underlying disease condition may trigger the pain. The therapy is aimed to provide symptomatic relief, and therefore, the treatment protocols have been established based on experience. Intravesical delivery of drugs has been well explored and found to be most effective in minimizing the symptoms of IC without systemic adverse events. However, the efficacy of drug absorption is limited by the bladder wall permeability and poor absorption of the instilled drugs. The intravesical approach should be coupled with novel nanocarriers such as nanoparticles or liposomes to overcome these limitations. Nanoparticles can easily cross the bladder permeability barrier and enhance the drug retention time in the bladder, making the delivery efficient and promising. This review addresses the current IC management strategies, new potential therapeutic agents of natural origin, and various drugs undergoing clinical trials by different routes of administration.
650		0	_94639 _aPHARMACEUTICS
700			_98814 _aNair, Anroop
773	0		_x0019-5464 _tIndian journal of pharmaceutical education and research _dBengluru Association of Pharmaceutical Teachers of India (APTI)
856			_uhttps://ijper.org/sites/default/files/IndJPhaEdRes-56-3-636_0.pdf _yClick here
942			_2ddc _cAR